Invasive fungal infections in healthcare settings
pdf

Keywords

invasive fungal infections
healthcare settings
Maria BALASOIU

How to Cite

BALASOIU, M. (2023) “Invasive fungal infections in healthcare settings”, One Health & Risk Management , 4(4), p. 3. Available at: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/564 (Accessed: 1July2025).

Abstract

The incidence of invasive infections produced by species of the Candida genus is continuously raising, Candida is the 5th most common pathogen in invasive infections. Although most of the fungal invasive infections are produced by Candida albicans, there are increasing reports of other non-albicans species that produce severe infections because have increased pathogenicity and resistance to commonly used fungal agents, with high mortality rates. Non-albicans Candida species identified in recent years include C. glabrata, C. parapsilosis, C. tropicalis and C. auris, the last seems to have uniquely high transmissibility in hospital environments and also between healthcare settings. C. auris outbreaks are systematically reported in recent years, and molecular investigation had confirmed the intra-hospital transmission. The first reported invasive infection with C. auris was in South Korea in 1996, since then outbreaks had been reported in more than 40 countries on 6 continents. Recently, Candida isolates have demonstrated increased resistance to azoles, amphotericin B and echinocandins, many strains are multidrug-resistant or even pan-resistant. The national health services must enforce preventive measures of invasive fungal infections, especially in high-risk patient groups such as those with impaired immune systems (anticancer drugs, long-term corticoid treatments, solid organ transplant and other chronic diseases). The laboratories must be prepared to identify this emerging fungal pathogen by at least biochemical methods, but it is recommended to use molecular methods as PCR, MLST, and MALDI-TOF MS. Screening protocols must be implemented in all patients at risk.

pdf

|Views: 273| |pdf Downloads: 126|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Maria BALASOIU

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370